Preclinical trials of a new radiopharmaceutical to treat ovarian cancer have produced successful results, dramatically limiting tumor growth and decreasing tumor mass.
Reston, VA-Preclinical trials of a new radiopharmaceutical to treat ovarian cancer have produced successful results, dramatically limiting tumor growth.
Case Western Reserve University researcher Farren Briggs was awarded $1.2 million over three years from the National Institute of Neurological Disorders and Stroke at the National Institutes of Health to identify biomarkers to improve the diagnoses of multiple sclerosis, including the ability to monitor disease activity and progression.
Preclinical trials of a new radiopharmaceutical to treat ovarian cancer have produced successful results, dramatically limiting tumor growth and decreasing tumor mass. Designed specifically for ovarian cancers that are resistant to traditional therapies, the new radiopharmaceutical can be produced in 25 minutes at low cost, which leads to better efficiency compared with alternative methods. This research was presented at the Society of Nuclear Medicine and Molecular Imaging 2021 Annual Meeting.
It can be easy to forget that the human skin is an organ. It's also the largest one and it's exposed, charged with keeping our inner biology safe from the perils of the outside world.